Literature DB >> 15341591

Deletion of the adenosine A1 receptor gene does not alter neuronal damage following ischaemia in vivo or in vitro.

Tomas Olsson1, Tobias Cronberg, Anna Rytter, Fredrik Asztély, Bertil B Fredholm, Maj-Lis Smith, Tadeusz Wieloch.   

Abstract

Extracellular adenosine is dramatically increased during cerebral ischaemia and is considered to be neuroprotective due to its inhibitory effect on synaptic transmission mediated by the adenosine A1 receptor (A1R). We investigated the importance of the A1R in a mouse model of global ischaemia and in a murine hippocampal slice culture model of in vitro ischaemia, using mice with the A1R gene deleted. In brains from mice lacking the A1R, damage induced by global ischaemia was similar to that in wild-type animals. In contrast, treatment with a selective A1R antagonist [8-cyclo-pentyl theophylline (8-CPT)], administered before the ischaemic insult in naive wild-type mice, exacerbated the neuronal damage following global ischaemia. Although the inhibitory action of adenosine on excitatory neurotransmission in hippocampal slices was lost in A1R knockout mice, there was no difference in damage between slices from wild-type and knockout mice after in vitro ischaemia. The results suggest that some effects of the A1R are compensated for in knockout animals.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15341591     DOI: 10.1111/j.1460-9568.2004.03564.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  23 in total

1.  Purines and the Anti-Epileptic Actions of Ketogenic Diets.

Authors:  Susan A Masino; Masahito Kawamura; David N Ruskin; Jeremy Gawryluk; Xuesong Chen; Jonathan D Geiger
Journal:  Open Neurosci J       Date:  2010-01-01

Review 2.  Adenosine receptors as therapeutic targets.

Authors:  Kenneth A Jacobson; Zhan-Guo Gao
Journal:  Nat Rev Drug Discov       Date:  2006-03       Impact factor: 84.694

3.  Caffeine exposure ameliorates acute ischemic cell death in avian developing retina.

Authors:  D Pereira-Figueiredo; R Brito; D S M Araújo; A A Nascimento; E S B Lyra; A M S S Cheibub; A D Pereira Netto; A L M Ventura; R Paes-de-Carvalho; K C Calaza
Journal:  Purinergic Signal       Date:  2020-02-20       Impact factor: 3.765

4.  Adenosine kinase determines the degree of brain injury after ischemic stroke in mice.

Authors:  Hai-Ying Shen; Theresa A Lusardi; Rebecca L Williams-Karnesky; Jing-Quan Lan; David J Poulsen; Detlev Boison
Journal:  J Cereb Blood Flow Metab       Date:  2011-03-23       Impact factor: 6.200

5.  Mdivi-1 Protects Against Ischemic Brain Injury via Elevating Extracellular Adenosine in a cAMP/CREB-CD39-Dependent Manner.

Authors:  Mei Cui; Hongyan Ding; Fangzhe Chen; Yanxin Zhao; Qi Yang; Qiang Dong
Journal:  Mol Neurobiol       Date:  2014-11-27       Impact factor: 5.590

Review 6.  Targeting astrocytes for stroke therapy.

Authors:  Yanxin Zhao; David A Rempe
Journal:  Neurotherapeutics       Date:  2010-10       Impact factor: 7.620

7.  Adenosine and stroke: maximizing the therapeutic potential of adenosine as a prophylactic and acute neuroprotectant.

Authors:  Rebecca L Williams-Karnesky; Mary P Stenzel-Poore
Journal:  Curr Neuropharmacol       Date:  2009-09       Impact factor: 7.363

Review 8.  Adenosine signaling and function in glial cells.

Authors:  D Boison; J-F Chen; B B Fredholm
Journal:  Cell Death Differ       Date:  2009-09-18       Impact factor: 15.828

9.  Overexpression of UCP2 protects thalamic neurons following global ischemia in the mouse.

Authors:  Tomas Deierborg; Tomas Deierborg Olsson; Tadeusz Wieloch; Sabrina Diano; Craig H Warden; Tamas L Horvath; Gustav Mattiasson
Journal:  J Cereb Blood Flow Metab       Date:  2008-02-27       Impact factor: 6.200

10.  Adenosine A1 receptors contribute to immune regulation after neonatal hypoxic ischemic brain injury.

Authors:  Max Winerdal; Malin E Winerdal; Ying-Qing Wang; Bertil B Fredholm; Ola Winqvist; Ulrika Ådén
Journal:  Purinergic Signal       Date:  2015-11-25       Impact factor: 3.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.